| Rolando Rodriguez, | |
|
3601 4th St, Lubbock, TX 79430-8143 | |
| (806) 743-2770 | |
| (806) 743-3955 |
| Full Name | Rolando Rodriguez |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 3601 4th St, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497101190 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | BP10056161 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Calvert Home Health Care Ltd | Lubbock, TX | Home health agency |
| Legacy Of Love Hospice | Littlefield, TX | Hospice |
| Lamb Healthcare Center | Littlefield, TX | Hospital |
| Covenant Hospital Plainview | Plainview, TX | Hospital |
| University Medical Center | Lubbock, TX | Hospital |
| Arbor Grace Wellness Center | Littlefield, TX | Nursing home |
| Entity Name | Lamb Healthcare Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700854288 PECOS PAC ID: 6103738471 Enrollment ID: O20040127000737 |
News Archive
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.
Bruker, the leader in analytical magnetic resonance instrumentation, announces a major multi-systems NMR order from Vanderbilt University, including an ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase was made possible in large part by the American Recovery and Reinvestment Act. Vanderbilt will use these NMR instruments for a broad range of biophysical and structural analyses in biomedical research, as well as for cancer drug discovery using fragment-based approaches and structure-based drug design.
A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.
› Verified 1 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.
Bruker, the leader in analytical magnetic resonance instrumentation, announces a major multi-systems NMR order from Vanderbilt University, including an ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase was made possible in large part by the American Recovery and Reinvestment Act. Vanderbilt will use these NMR instruments for a broad range of biophysical and structural analyses in biomedical research, as well as for cancer drug discovery using fragment-based approaches and structure-based drug design.
A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.
› Verified 1 days ago
| Entity Name | Rolando Rodriguez Md |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801418884 PECOS PAC ID: 1052721354 Enrollment ID: O20201027002092 |
News Archive
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.
Bruker, the leader in analytical magnetic resonance instrumentation, announces a major multi-systems NMR order from Vanderbilt University, including an ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase was made possible in large part by the American Recovery and Reinvestment Act. Vanderbilt will use these NMR instruments for a broad range of biophysical and structural analyses in biomedical research, as well as for cancer drug discovery using fragment-based approaches and structure-based drug design.
A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rolando Rodriguez, 3601 4th St, Lubbock, TX 79430-8143 Ph: (806) 743-2770 | Rolando Rodriguez, 3601 4th St, Lubbock, TX 79430-8143 Ph: (806) 743-2770 |
News Archive
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.
Bruker, the leader in analytical magnetic resonance instrumentation, announces a major multi-systems NMR order from Vanderbilt University, including an ultra-high field AVANCE™ III 900 US2 NMR spectrometer. This purchase was made possible in large part by the American Recovery and Reinvestment Act. Vanderbilt will use these NMR instruments for a broad range of biophysical and structural analyses in biomedical research, as well as for cancer drug discovery using fragment-based approaches and structure-based drug design.
A Jackson Laboratory research team led by Professor Patsy Nishina, Ph.D., has identified a mutation in a gene that's essential for correct protein-processing in cells. Defects in protein folding are associated with a variety of abnormalities and diseases.
› Verified 1 days ago
Charles Hudson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Concord Medical Group, 1602 Avenue Q, Lubbock, TX 79401 Phone: 972-829-6613 Fax: 800-611-5029 | |
Dr. Ronald L. Cook, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3502 9th St, Suite 1c143, Lubbock, TX 79430 Phone: 806-743-2757 Fax: 806-743-2563 | |
Dr. Scott W. Dahlbeck, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 602 Indiana Ave, Lubbock, TX 79415 Phone: 806-775-8600 Fax: 806-775-8608 | |
Naticia Mortensen, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5915 82nd St, Lubbock, TX 79424 Phone: 806-794-3000 Fax: 806-698-0847 | |
Ryan Daniel Lurtsema, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 4th Street Mail Stop 9901, Lubbock, TX 79430 Phone: 806-743-2757 Fax: 806-743-1180 | |
Dr. Cherrylene A Lindgren, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4105 I-27, Lubbock, TX 79404 Phone: 806-762-2633 Fax: 806-761-0431 | |
Jared Zachary Brinker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4515 Marsha Sharp Fwy, Lubbock, TX 79407 Phone: 806-744-7223 Fax: 806-740-3325 |